PNH - Please select who you are:

Diagnosing PNH

Early diagnosis is essential for improved patient management and prognosis1,2

The International Clinical Cytometry Society (ICCS) guidelines and multiple other experts have identified groups of patients at high risk for PNH1-7

The ICCS Guidelines identify patient populations at high risk for PNH2

PNH symptom incidence rate

  • Routinely evaluate high-risk patient types for PNH: these include patients with unexplained cytopenias, aplastic anemia, myelodysplastic syndromes, unexplained thrombosis, Coombs-negative hemolytic anemia, and hemoglobinuria2
  • The ICCS Guidelines recommend high-sensitvity (0.01% PNH cell threshold) flow cytometry testing on patients at high risk for PNH2,7
  • Early diagnosis and intervention are critical1,2

PNH symptom incidence rate

A clinical assessment is crucial to determine the risk for morbidities and premature mortality in your patient with PNH4,8,9


  • PNH presents uniquely in each patient, and outward symptomatology may be general and common2
  • Rule PNH in or out using high-sensitivity flow cytometry on a peripheral blood sample2,7
  • Appropriate clinical assessment of the patient along with lab results provide a more complete diagnostic picture4,8,9

Monitor patients with small PNH clones since clone size can expand unpredictably over time11

This information is intended as educational information for health care professionals. It does not replace a health care professional's judgement or clinical diagnosis.


Early diagnosis is essential for improved patient management and prognosis. Learn about ICCS and other expert recommendations for who should be tested for PNH.

The ICCS and IPIGc have identified patient populations at high risk for PNH. Download a toolkit that provides specific information about each of these high-risk groups.

cIPIG = International PNH Interest Group.

References: 1. Morado M, et al. Cytometry B Clin Cytom. 2017;92(5):361-370. 2. Borowitz MJ, et al. Cytometry B Clin Cytom. 2010;78(4):211-230. 3. Sharma VR. Clin Adv Hematol Oncol. 2013;11 Suppl 13(9):2-8. 4. Parker C, et al. Blood. 2005;106(12):3699-3709. 5. Rachidi S, et al. Eur J Intern Med. 2010;21(4):260-267. 6. Hill A, et al. Blood. 2013;121(25):4985-4996. 7. Dezern AE, et al. Cytometry B Clin Cytom. 2018;94(1):16-22. 8. Hill A, et al. Br J Haematol. 2010;149(3):414-425. 9. Weitz I, et al. Intern Med J. 2013;43(3):298-307. 10. Parker CJ. Hematology Am Soc Hematol Educ Program. 2016;2016(1):208-216. 11. Pu JJ, Eur J Haematol. 2011;87(1):37-45.